Plus therapeutics to host investor call to discuss leptomeningeal cancer related acquisition and topline clinical trial data from the foresee trial

Company acquired all assets for the synergistic cnside cerebrospinal fluid diagnostic portfolio company will summarize topline data from the foresee clinical trial planned for presentation at the sno/asco meeting in august 2024 management call scheduled for thursday, may 9th, 2024 at 8:30 am et austin, texas, may 08, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announces it will host an investor call on thursday, may 9th, 2024 at 8:30 am et to discuss the strategic acquisition of the cnside cerebrospinal fluid (csf) testing assets. during the call, president and chief executive officer dr. marc h.
pstv Ratings Summary
pstv Quant Ranking